Bavarian Nordic A/S
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.
Contact investors:
Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03
Company Announcement no. 42 / 2025
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Bavarian Nordic A/S10.11.2025 21:00:00 CET | Pressemeddelelse
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley
North Atlantic10.11.2025 20:51:05 CET | Press release
North Atlantic France SAS provides updates on the contemplated acquisition of a majority stake in Esso Société Anonyme Française SA
Glunz & Jensen Holding A/S10.11.2025 19:02:01 CET | Press release
Purchase of shares
Verkkokauppa.com Oyj10.11.2025 18:00:00 CET | Press release
Verkkokauppa.com Oyj: Acquisition of own shares on 10 November 2025
Syensqo SA10.11.2025 17:45:00 CET | Press release
Syensqo - Acquisition of own shares
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom